CNBC July 2, 2021
Key Points
– CRISPR gene editing, which slices DNA to treat diseases, had its first-ever systemic delivery in a human body.
– Intellia Therapeutics CEO John Leonard said it was a “major advance in the gene editing space.”
– Intellia saw its stock rise over 100% in June; 90% in the past week alone since its breakthrough in a collaboration with Regeneron was announced.
Following a breakthrough trial where gene-editing technology CRISPR completed its first systematic delivery as medicine to a human body, Intellia Therapeutics CEO John Leonard said he hopes the gene therapy could be made available to patients “very, very soon.”
“These approaches are subjected to the standard sorts of clinical trials that any drug or gene therapy...
Today's Sponsors
Today's Sponsor